Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium

Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening a...

Full description

Saved in:

Bibliographic Details
Published in:	The International journal of drug policy Vol. 124; p. 104309
Main Authors:	Lancaster, Kathryn E., Stockton, Melissa, Remch, Molly, Wester, C. William, Nash, Denis, Brazier, Ellen, Adedimeji, Adebola, Finlayson, Robert, Freeman, Aimee, Hogan, Breanna, Kasozi, Charles, Kwobah, Edith Kamaru, Kulzer, Jayne Lewis, Merati, Tuti, Tine, Judiacel, Poda, Armel, Succi, Regina, Twizere, Christelle, Tlali, Mpho, Groote, Per von, Edelman, E. Jennifer, Parcesepe, Angela M.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-02-2024
Subjects:	Alcohol use Availability HIV Screening Substance use Treatment Substance use Availability Screening Treatment HIV Alcohol use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening and treatment availability in HIV clinical sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. In 2020, 223 IeDEA HIV clinical sites from 41 countries across seven geographic regions completed a survey on capacity and practices related to management of AUD/ SUD. Sites provided information on AUD and other SUD screening and treatment practices. Sites were from low-income countries (23%), lower-middle-income countries (38%), upper-middle income countries (17%) and high-income counties (23%). AUD and SUD screening using validated instruments were reported at 32% (n=71 located in 12 countries) and 12% (n=27 located in 6 countries) of the 223 sites from 41 countries, respectively. The North American region had the highest proportion of clinics that reported AUD screening (76%), followed by East Africa (46%); none of the sites in West or Central Africa reported AUD screening. 31% (n=69) reported both AUD screening and counseling, brief intervention, psychotherapy, or Screening, Brief Intervention, and Referral to Treatment; 8% (n=18) reported AUD screening and detox hospitalization; and 10% (n=24) reported both AUD screening and medication. While the proportion of clinics providing treatment for SUD was lower than those treating AUD, the prevalence estimates of treatment availability were similar. Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0955-3959 1873-4758
DOI:	10.1016/j.drugpo.2023.104309